ZOLINZA

This brand name is authorized in United States. It is also authorized in Australia, Canada, Japan, Mexico.

Active ingredients

The drug ZOLINZA contains one active pharmaceutical ingredient (API):

1	Vorinostat UNII 58IFB293JI - VORINOSTAT
	Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells.
	Read more about Vorinostat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZOLINZA Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XH01	Vorinostat	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors
Discover more medicines within L01XH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11138F, 11141J
CA	Health Products and Food Branch	02327619
JP	医薬品医療機器総合機構	4291025M1029
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	063M2010
US	FDA, National Drug Code	0006-0568